Generated with Avocode.Line 2Line 3

AI Insights to Impact:
Virtual Panel Discussion with Drs Kumar, Heit and Ms Philpot

Tuesday, December 10, 4:30 PM PST
Reserve Your Spot
Customer Support
Contact
    Contrast Shortage Resource Center

    Maintain Stroke Care
    and Patient Safety

    We’re here to help. Patient safety and stroke workflow efficiency are our #1 priority. Working with industry leaders, experts, and our customers, we’ve developed a set of resources to help imaging teams manage through the current contrast shortage situation. 

    MRI has been identified by the FDA, the American College of Radiology, and other expert institutions as an alternative solution for contrast imaging. The content below will be useful for those who are considering switching from CT to MR for acute stroke imaging protocols, including details on Rapid MRI, an excellent alternative to your current CT scan protocol for stroke patients. 

    Contrast-Shortage_hero
    faq_icon

    Get answers to frequently asked questions

    What is the recommended reduced contrast dose for CTP?
    According to ACR–ASNR–SPR Practice Parameter for the Performance of Computed Tomography (CT) Perfusion in Neuroradiologic Imaging: The total volume and injection rate of contrast material should be optimized for each pathophysiologic situation being investigated, with a minimum volume of 40 mL and a minimum injection rate of 4 mL/s. The higher the injection rate, the better the peak opacification and the better the image and temporal curve quality, which in turn determines the quality of the constructed hemodynamic maps.
    What is the recommended reduced contrast dose for CTA?
    According to ACR–ASNR–SPR Practice Parameter for the Performance and Interpretation of Cervicocerebral Computed Tomography Angiography (CTA): Ideally the administration of iodinated contrast media for the CTA should be performed with a minimum flow rate of 4 mL/s in any patient weighing 50 kg or more. Higher flow rates up to 6 mL/s are frequently required for larger patients, and in general, higher flow rates are required for shorter acquisitions. For patients under 50 kg, a dose of 2 mL/kg should be considered.  
    Are there other contrast agents that can be substituted for Omnipaque and Isovue?
    We most commonly see Omnipaque-350 and Isovue-370 utilized for CTA and CTP imaging. However, there may be other options available to your department from others within your facility or your contrast media supplier. In addition, many facilities and imaging departments are putting in place tiered systems to manage and prioritize contrast conservation, as well as updating protocols and workflows to utilize shortened exams and non-contrast options—all while ensuring optimal patient care. Please see some of the resources listed below for additional guidance. 
    Are there ways to enhance the CTP and CTA protocols that we are currently utilizing?
    Yes, adjustments can be made to variables such as slice thickness, field-of-view and kV. The RapidAI Implementation and Image Quality teams can review your current protocols and provide recommendations or guide you to additional information. Please reach out to support@rapidai.com.
    Can our site utilize MR in place of CT for acute stroke?
    Yes, Rapid MRI provides analysis of both diffusion- and perfusion-weighted images, and is the only advanced imaging product for acute stroke indicated to identify patients eligible for thrombectomy. For more information contact support@rapidai.com.
    Are there fast MR sequences that can be used for 1.5T and for 3T scanners?
    Yes, the RapidAI Implementation and Image Quality team can discuss fast MR sequences used for acute stroke screening. Contact support@rapidai.com. You can also find suggestions in the videos above. 
    Where can I find additional information?
    About Rapid MRI

    About Rapid MRI

    Rapid MRI is the only FDA-cleared advanced imaging product available that automatically delivers clinically proven, advanced MR diffusion and perfusion image analysis and is indicated by the FDA to identify patients eligible for thrombectomy.

    Contact us about considerations for reduced contrast usage, Rapid MRI, and other RapidAI clinical modules.

    Contact Us
    RapidAILogo_New
    The Next Evolution in Clinical Decision Making and Patient Workflow

    Sign Up for Email Updates

    Follow us on social:

    Products and Solutions

    Company

    News & Events

    ® RapidAI and Rapid are registered trademarks of iSchemaView, Inc. | Privacy Policy